Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BLOOD-dose: adaptive multidomain platform trial for dose optimization in adult haematological diseases
2026-525658-13-00Phase 4Authorised
- Sponsor
- Capital Region of Denmark
- Start
- Jun 2026
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of ibrutinib, zanubrutinib, elranatamab, teclistamab and talquetamab in Hematopathy, lymphoma, multiple myeloma (MM) and 3 more, sponsored by Capital Region of Denmark. Primary endpoint: Overall survival. Planned start Jun 2026; status: authorised.
02
Drugs
ibrutinibzanubrutinibelranatamabteclistamabtalquetamab
03
Conditions
Hematopathylymphomamultiple myeloma (MM)leukemiamyelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2026-525658-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525658-13-00.